Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

AptarGroup, Inc. ATR

Healthcare — Medical Instruments & Supplies
Dividend Champion (5y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
7.82
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 1 — 2 — — 2 2 — 4 1
Insider Ownership
1.97%

Capital & Financial Ratios

Market Cap
7,980.00
Revenue
3,933.24
Net Income
362.88
Free Cash Flow
314.58
Net Debt
1,170.39
Current Ratio
1.61
Debt/Equity
0.52
P/E ratio
22.22
P/S ratio
2.01
P/B ratio
2.99
Past 5Y EPS Growth
8.59%
This Y EPS Growth
(3.88%)
Next Y EPS Growth
14.50%
Next 5Y EPS Growth
7.47%
in millions of $

Dividends

Payout Ratio
0.40
Annual Dividend Rate
1.64
Annual Dividend Yield
1.37%
total individual payouts
2028 ‡‡‡‡
2027 ‡‡‡‡‡
2026 1.95
—
—
—
2025 1.83
—
—
—
—
2024 1.72
—
—
—
—
2023 1.58
—
—
—
—
2022 1.52
—
—
—
—
2021 1.50
—
—
—
—
2020 1.44
—
—
—
—
2019 1.42
—
—
—
—
2018 1.32
—
—
—
—
2017 1.28
—
—
—
—
2016 1.22
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 223.64 226.18 409.53 197.27
Receivables 677.82 658.06 803.83 897.66
Inventory 513.05 461.81 537.85 580.14
Other — — — —
1,549.28 1,478.38 1,893.56 1,834.82
2023 2024 2025 Q'26
Payables 793.09 730.00 822.91 887.31
ST’ Debt 376.43 338.29 343.53 249.24
Other — — — —
1,251.31 1,068.28 1,166.44 1,136.55
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 982.87 1,026.51 — —
—
’25 887.31 966.01 961.13 962.74
3,777.18
’24 915.45 910.06 909.29 848.09
3,582.89
’23 860.07 895.91 893.00 838.48
3,487.45
’22 844.93 844.54 836.86 795.91
3,322.25
’21 776.75 811.03 825.44 813.99
3,227.22
’20 721.55 699.31 759.15 749.33
2,929.34
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 118.69 103.49 — —
—
’25 82.74 125.96 177.61 183.69
570.00
’24 92.33 143.58 229.26 178.24
643.41
’23 98.30 83.90 173.40 219.64
575.24
’22 92.08 84.58 129.70 172.27
478.62
’21 72.19 103.40 83.79 104.07
363.44
’20 85.03 142.65 153.74 188.73
570.15
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 54.03 46.93 — —
—
’25 23.48 61.00 116.02 97.60
298.11
’24 16.85 76.22 149.47 108.19
350.73
’23 20.46 8.97 97.36 135.39
262.18
’22 19.47 10.43 45.91 87.29
163.09
’21 8.62 34.49 4.49 13.14
60.74
’20 19.62 85.60 102.00 116.15
323.37
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.12 1.36 — —
—
’25 1.17 1.67 1.92 1.13
5.89
’24 1.23 1.34 1.48 1.49
5.53
’23 0.82 1.24 1.26 0.93
4.25
’22 0.93 0.95 0.81 0.89
3.59
’21 1.24 0.81 0.70 0.85
3.61
’20 0.84 0.63 0.95 0.79
3.21

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 90.23 107.89 122.29 103.23 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 124.14 133.79 178.03 164.28 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,500 13,800 13,500 14,000 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.25 0.25 0.27 0.27 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,322.25 3,487.45 3,582.89 3,777.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.03% 36.23% 37.83% 37.19% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 334.70 374.83 469.77 491.38 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.07% 10.75% 13.11% 13.01% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 239.56 284.18 374.18 392.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 233.71 248.59 263.78 287.36 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.80 53.15 54.01 57.46 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.66 4.34 5.65 5.97 ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.32 8.77 9.70 8.67 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.82) (4.77) (4.41) (4.14) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.49 4.00 5.29 4.53 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.62 35.38 37.48 40.86 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.40 65.62 66.33 65.74 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.21 28.31 27.81 20.43 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.17 2.31 2.91 2.12 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.49 3.47 4.19 2.99 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.48 2.55 3.13 2.41 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51.31 33.93 31.99 30.50 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 478.62 575.24 643.41 570.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (315.52) (313.05) (292.68) (271.89) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 163.09 262.18 350.73 298.11 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 513.12 297.97 410.10 727.12 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,171.58 1,057.61 1,026.35 1,482.96 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,029.85 833.97 800.17 1,073.43 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,068.20 2,321.30 2,485.92 2,685.98 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 5.74% 6.57% 8.43% 8.11% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.65% 8.00% 9.44% 8.33% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.81% 12.96% 15.58% 15.19% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

AptarGroup, Inc. (ATR), a leader in specialized packaging for pharmaceuticals, beauty, and food sectors, has delivered resilient revenue growth from $2.33 billion in 2016 to $3.58 billion in 2024 (5.5% CAGR), fueled by pandemic-driven pharma demand and operational efficiency, with revenue per employee rising 44% to $265,000. Profitability has strengthened markedly, with EBT margins hitting a record 13.1% and EPS jumping 30% to $5.65 in 2024, supported by rebounding gross margins and robust free cash flow per share more than doubling to $5.29.

Projections signal continued momentum—revenue to $4.39 billion by 2028 (5-6% CAGR), EPS to $6.85 (21% gain)—but moderating growth post-pandemic tailwinds, rising debt to $1.48 billion in 2025, and $11 million in insider selling (no buys) introduce caution amid a solid balance sheet and conservative dividend policy. Valuation appears balanced near recent highs, with PE at 27.8x and modest 7% upside to targets, evoking steady industrials like Amcor.

A hold for long-term portfolios offers 5-7% annual returns via earnings and FCF, but monitor debt trends, margins, and Q1 2026 earnings for execution risks in a volatile macro environment.

Read full commentary →

AptarGroup, Inc. (ATR) Latest News

News by impact score

Fine-tune

14 Sep

3 , 5:00 PM
Aptar Pharma collaborates with Massachusetts General Hospital to build a platform establishing predictive data-driven models for advancing nose-to-brain drug delivery. Research collaboration strengthens Aptar Pharma's drug delivery innovation pipeline with moderate long-term upside.

5 Aug

3 , 10:28 AM
AptarGroup Q2 earnings exceeded estimates due to growth in Pharma and Beverage segments. Q2 earnings beat signals improved performance in core segments with moderate effects on near-term trajectory.

3 Aug

3 , 9:15 AM
AptarGroup's international revenue trends are key indicators for assessing the company's growth potential and overall market performance. International revenue trends may moderately influence AptarGroup's financial performance and competitive positioning.

31 Jul

4 , 5:01 PM
AptarGroup Inc (ATR) posted record sales in Q2 2026 earnings call alongside strategic wins. Record sales and strategic wins signal major positive shifts in financial performance and positioning.

3 transcript www.marketbeat.com, 12:04 PM
AptarGroup Q2 earnings call highlighted financial results, segment performance, and management outlook. Quarterly earnings updates typically affect near-term stock sentiment and analyst views without shifting long-term strategy.

3 transcript app.moby.co, 8:30 AM
AptarGroup reported Q2 2026 earnings results including revenue, margins, segment performance and forward guidance during its earnings call. Quarterly earnings and guidance provide moderate influence on near-term financial expectations and stock movement.

30 Jul

3 , 5:00 PM
AptarGroup reported second quarter 2026 financial results. Quarterly results update financial metrics and may shift short-term investor views without altering core trajectory.

20 Jul

3 , 5:00 PM
Aptar Beauty launches next-generation auto-loading dropper technology for easier and more accurate skincare dosing. Product launch adds incremental innovation to core beauty dispensing segment with limited company-wide effects.

9 May

4 www.marketbeat.com, 6:06 PM
AptarGroup announces CEO succession plan amid rising 2025 sales and shareholder approval of ballot measures. CEO succession represents a major strategic leadership shift alongside positive sales growth and shareholder endorsement.

6 May

4 Business Wire, 5:00 PM
AptarGroup partners with Clarins on patented reloadable airless packaging innovation, advancing sustainability features in luxury beauty products. Patented sustainability innovation with Clarins enhances Aptar's competitive edge in luxury packaging market.

3 Zacks, 10:14 AM
AptarGroup's Q1 earnings beat analyst estimates despite a year-over-year decline, prompting a 1% dip in shares. Q1 earnings beat estimates but declined year-over-year, causing a minor share price dip with moderate influence on financial performance.

3 May

4 Simply Wall St., 9:09 AM
AptarGroup, Inc. (NYSE:ATR) reported first-quarter results, prompting analysts to update their forecasts. Q1 earnings release and analyst forecast updates signal potential shifts in financial outlook and investor sentiment.

2 May

3 GuruFocus.com, 3:02 AM
AptarGroup Inc (ATR) reported strong sales growth in Q1 2026 earnings call highlights, amid operational challenges. Strong sales growth despite operational hurdles indicates moderately positive influence on financial performance and market sentiment.

3 , 12:28 AM
AptarGroup (ATR) exceeded first-quarter earnings expectations despite profit softness, triggering a valuation reassessment. Q1 earnings beat offset by profit softness moderately affects financial performance and investor sentiment without major trajectory shifts.

1 May

4 app.moby.co, 8:30 AM
AptarGroup, Inc. (ATR) released Q1 2026 earnings call summary highlighting financial results, operational updates, and forward guidance. Q1 2026 earnings call summary reveals financial performance and strategic outlook that significantly shape investor expectations and stock trajectory.

3 www.marketbeat.com, 11:28 AM
AptarGroup's Q1 earnings call highlighted financial results, segment performance, and updated full-year guidance. Q1 earnings highlights reveal financial performance and outlook, moderately influencing investor sentiment and stock trajectory.

30 Apr

4 Business Wire, 5:00 PM
AptarGroup, Inc. (ATR) reported first quarter 2026 results. Quarterly earnings reports significantly affect financial metrics, investor sentiment, and stock performance.

3 Zacks, 6:25 PM
AptarGroup (ATR) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates signals strong quarterly financial performance, moderately boosting investor sentiment and near-term stock trajectory.

27 Apr

3 Business Wire, 5:09 PM
AptarGroup launches inverted lidless dispensing closures that turn beauty and personal care products upside down for clean, single-handed dispensing. Innovative dispensing closures strengthen AptarGroup's product portfolio in beauty and personal care, with moderate impact on competitive positioning.

23 Apr

3 Zacks, 10:00 AM
AptarGroup (ATR) Q1 earnings expected to decline amid analyst previews highlighting weaker performance. Expected Q1 earnings decline signals moderately noticeable pressure on financial results and market sentiment.

8 Apr

4 , 5:00 PM
Aptar Digital Health partners with Enable Injections to integrate enFuse® Companion digital solution with Enable's on-body injector platform, providing connectivity, real-time data tracking, reminders, and support to enhance patient experience in self-injection therapies. Partnership advances AptarGroup's digital health capabilities in drug delivery, positioning it for revenue growth through innovative patient-centric solutions.

4 Business Wire, 4:00 PM
Aptar Digital Health partners with Enable Injections to develop enFuse® Companion Digital Solution, integrating digital features with on-body injector technology for enhanced patient experience and data connectivity. Partnership expands AptarGroup's digital health portfolio with innovative companion technology for drug delivery, boosting competitive edge and revenue potential.

17 Mar

4 Business Wire, 5:00 PM
AptarGroup, Inc. (ATR) named Gael Touya as its next Chief Executive Officer, succeeding Stephan B. Tanda, who will retire by the end of the year. CEO succession signals potential strategic shifts that could significantly impact long-term direction and market perception.

16 Mar

3 Business Wire, 5:00 PM
AptarGroup's intranasal delivery system is being used in a Phase II clinical study for the investigational SPONTAN® nasal spray. Validation in Phase II study for nasal spray strengthens Aptar's position in drug delivery systems and pharma partnerships.

28 Feb

4 www.fool.com, 4:47 PM
River Road Asset Management initiated a substantial new position in AptarGroup, Inc. (ATR) by purchasing 917,000 shares. River Road's large new 917,000-share stake in ATR signals strong institutional confidence, likely enhancing investor sentiment and stock performance.

10 Feb

4 ZacksZacksZacksZacksZacksZacksZacksZacks, 9:15 AM
AptarGroup, Inc. (ATR) is experiencing notable trends in international revenue, which are crucial for investors to consider when evaluating the stock. The company's global operations are showing resilience and growth potential, particularly in emerging markets. Analysts emphasize the importance of these international revenue streams in understanding AptarGroup's overall financial health and future prospects. Investors are encouraged to focus on these trends as they could significantly influence the company's market performance. International revenue trends are likely to significantly impact AptarGroup's future performance and investor sentiment.

9 Feb

4 Simply Wall St., 11:29 PM
AptarGroup, Inc. announced a new earnings guidance and a US$600 million share buyback program, which has garnered significant interest from investors. The company's valuation is being closely examined in light of these developments, indicating potential shifts in market sentiment and financial performance. Analysts are evaluating how these strategic moves may influence AptarGroup's competitive positioning and future growth prospects. The US$600 million buyback and updated earnings guidance are significant strategic moves that could notably impact investor sentiment and the company's trajectory.

4 Simply Wall St., 5:14 PM
AptarGroup, Inc. (ATR) shares rose 7.6% following the announcement of record sales and a new $600 million share buyback program. The company's strong financial performance and strategic move to enhance shareholder value have sparked discussions about its future prospects and market positioning. The $600 million buyback and record sales indicate significant strategic moves that could positively influence investor sentiment and the company's trajectory.

4 , 6:18 AM
AptarGroup, Inc. (ATR) is identified as having an intrinsic value potentially 58% above its current share price, suggesting significant upside for investors. Analysts highlight the company's strong fundamentals and growth prospects, indicating that the market may not fully recognize its value. This discrepancy presents an opportunity for investors looking for undervalued stocks in the market. The potential intrinsic value significantly above the current share price indicates a likely substantial impact on investor sentiment and future performance.

6 Feb

4 transcript www.marketbeat.com, 5:33 PM
AptarGroup, Inc. reported its Q4 earnings, highlighting strong financial performance driven by increased demand for its innovative packaging solutions. The company emphasized its commitment to sustainability and expanding its product offerings to meet evolving consumer needs. Management provided insights into future growth strategies and market trends, indicating optimism for continued success in the upcoming quarters. Strong financial performance and strategic growth initiatives are likely to significantly impact future market positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us